NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HALO shares have decreased by 7.4% and is now trading at $16.87. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics.

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biopharmaceutical company earned $53.70 million during the quarter, compared to analysts' expectations of $55.69 million. Halozyme Therapeutics had a negative return on equity of 33.71% and a negative net margin of 36.86%. Halozyme Therapeutics's revenue was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) EPS. View Halozyme Therapeutics' earnings history.

Halozyme Therapeutics updated its FY20 earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus estimate of $0.59. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.15 million.

6 brokerages have issued 1 year price objectives for Halozyme Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they expect Halozyme Therapeutics' stock price to reach $25.33 in the next year. This suggests a possible upside of 50.2% from the stock's current price. View analysts' price targets for Halozyme Therapeutics.

News coverage about HALO stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutHalozyme Therapeutics.

Halozyme Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 13,870,000 shares, an increase of 7.9% from the February 13th total of 12,850,000 shares. Based on an average daily trading volume, of 1,580,000 shares, the short-interest ratio is currently 8.8 days. Currently, 10.7% of the shares of the stock are sold short. View Halozyme Therapeutics' Current Options Chain.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $16.87.

Halozyme Therapeutics has a market capitalization of $2.33 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. View additional information about Halozyme Therapeutics.

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]